Neuralstem presents clinical update this month in New York

KUALA LUMPUR, April 12 (Bernama) -- Neuralstem Inc´s chief scientific officer, Karl Johe Ph.D will give a clinical update at the Alliance for Regenerative Medicine 6th Annual Cell and Gene Therapy Investor Day in New York on April 17.

The Company has two lead development candidates, NSI-189 - a small molecule in clinical development for major depressive disorder and NSI-566, a stem cell therapy being tested for treatment of paralysis in stroke, Amyotrophic Lateral Sclerosis (ALS) and chronic spinal cord injury (cSCI).

A statement said a live audio webcast as well as a video recording of the presentation will be available in the Investors section of Company´s website at investor.neuralstem.com. The webcast will be archived on the Company's website for 90 days following the presentation.

Neuralstem is a clinical-stage biopharmaceutical company developing novel treatments for nervous system diseases of high unmet medical need.



-- BERNAMA